Bevacizumab combination therapy in heavily pretreated, recurrent cervical cancer - Monoclonal Antibodies

Bevacizumab combination therapy in heavily pretreated, recurrent cervical cancer
2 May 2006
Jason D. Wright, Dana Viviano, Matthew A. Powell, Randall K. Gibb, David G. Mutch, Perry W. Grigsby and Janet S. Rader
Gynecologic Oncology
Abstract
Objective.
To report the utility of the monoclonal, anti-vascular endothelial growth factor antibody bevacizumab in combination with cytotoxic chemotherapy for women with recurrent cervical cancer.
Methods.
A retrospective analysis of women with recurrent cervical cancer treated with bevacizumab combination therapy was performed.
Results.
Six patients were identified. The patients had a median of 3 prior regimens. All of the patients had multisite, metastatic disease. The combination regimen included IV 5-fluorouracil in 5 (83%) patients and capecitabine in one (17%) subject. Treatment was well tolerated. Grade 4 toxicity occurred in one patient who developed neutropenic sepsis. Clinical benefit (CR, PR, or SD) was noted in 67% of the subjects. This included 1 (17%) complete response, 1 (17%) partial response and two (33%) patients with stable disease. The median time to progression for the four women who demonstrated clinical benefit was 4.3 months.
Conclusions.
Combination bevacizumab is well tolerated and displayed encouraging anti-tumor activity in heavily pretreated recurrent cervical cancer.
Keywords: Bevacizumab; Cervical cancer; Angiogenesis; Biologic therapy